Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8494118 | 0.76 | SIGMAR1 (0.84) | SIGMAR1ADRA2ATMEM97HTR2A | |
| SCHEMBL11781458 | 0.75 | OPRD1 (0.46) | SIGMAR1HTR2ADRD2SLC6A2HTR2C | |
| SCHEMBL13744353 | 0.73 | SIGMAR1 (0.55) | SIGMAR1ADRA2ATMEM97 | |
| SCHEMBL13744400 | 0.71 | SIGMAR1 (0.50) | SIGMAR1ADRA2ATMEM97 | |
| SCHEMBL736557 | 0.71 | SIGMAR1 (0.52) | SIGMAR1ADRA2A | |
| SCHEMBL2360287 | 0.71 | SIGMAR1 (0.52) | SIGMAR1ADRA2A | |
| SCHEMBL3917884 | 0.71 | SIGMAR1 (0.42) | SIGMAR1ADRA2ATMEM97HTR2A | |
| SCHEMBL5271760 | 0.70 | — | — | |
| SCHEMBL25358487 | 0.69 | SIGMAR1 (1.00) | SIGMAR1ADRA2AHTR2A | |
| SCHEMBL3919858 | 0.69 | SIGMAR1 (0.71) | SIGMAR1ADRA2AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038287-B1 | SPIRO[BENZOPYRAN]OR SPIRO[BENZOFURAN]DERIVATIVES WHICH INHIBIT THE SIGMA RECEPTOR | ESTEVE LABOR DR (ES) | 2012-12-26 | — | — | EP | disclosed |
| US-20090209568-A1 | Spiro [Benzopyran] or Spiro [Benzofuran] Derivatives Which Inhibit the Sigma Receptor | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2009-08-20 | — | — | US | disclosed |
| US-20090209568-A1 | Spiro [Benzopyran] or Spiro [Benzofuran] Derivatives Which Inhibit the Sigma Receptor | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2009-08-20 | — | — | US | disclosed |
| WO-2007121976-A1 | SPIRO[BENZOPYRAN] OR SPIRO[BENZOFURAN] DERIVATIVES WHICH INHIBIT THE SIGMA RECEPTOR | LABORATORIOS DEL. DR. ESTEVE, S.A. (ES) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209568-A1 | Spiro [Benzopyran] or Spiro [Benzofuran] Derivatives Which Inhibit the Sigma Receptor | SIGMAR1, TMEM97, OPRD1 | SIGMAR1 1/4885ADRA2A 46/4885TMEM97 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.